🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Levels of Visfatin/NAMPT in Human Milk

Recruitingn/aAges any - anyAllPaolo Manzoni Study Group
NCT06487286 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic/predictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities * Maternal hospitalization * Acquisition of the informed consent form signed by the patient Exclusion Criteria: * Refusal of the patient to participate in the study * Presence of hypogalactia or agalactia in the patient
💊

What it tests

  • observational study
📍

Where

1 site
Ospedale degli Infermi - ASL BI
Ponderano, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy